The South Korean contract biopharmaceutical manufacturer Samsung Biologics intends to acquire the Swiss active pharmaceutical ingredient manufacturer Polypeptide. The company is offering CHF44.31 per share in cash, valuing Polypeptide at around CHF1.5 billion. Polypeptide’s board of directors supports the offer, both companies announced on Monday. The major shareholder, Draupnir Holding, which holds just under 56% of the shares, also intends to sell its stake. The offer is around 40% above the share price prior to the announcement of the takeover plans in April. Conditions for the deal include regulatory approval and the acceptance of at least two-thirds of the shares. Polypeptide manufactures so-called peptides. These are short protein building blocks used as active ingredients or components in modern medicines, for example to treat metabolic or hormonal disorders. Around 1,500 employees Founded in 1996, the active ingredient manufacturer traces its origins back to peptide ...
Full story here
Are you the author?
Previous post
See more for
Next post
Tags: Featured,global trade,newsletter
Home › 3) Swiss Markets and News › 3.) Swissinfo Business and Economy › Korean firm bids CHF1.5bn for Swiss pharma supplier Polypeptide
Previous post
Next post
Korean firm bids CHF1.5bn for Swiss pharma supplier Polypeptide
Published on July 20, 2026
Permanent link to this article: https://snbchf.com/2026/07/korean-firm-chf1-5bn-swiss-pharma-supplier-polypeptide/
Receive a Daily Mail from this Blog
Live Currency Cross Rates
On Swiss National Bank
-
SNB Sight Deposits: is stable 0.0 billion francs compared to the previous week
2026-07-28 -
Household wealth in 2025
2026-04-28 -
Heads up for NZD and CHF traders, RBNZ Gov Breman and SNB Chair Schlegel to speak
2026-04-15 -
Swiss franc appreciation has led to tighter monetary conditions – SNB minutes
2026-04-16 -
SNB’s Chairman Schlegel: A few months of negative inflation wouldn’t be a problem
2026-01-21
Main SNB Background Info
-
SNB Sight Deposits: is stable 0.0 billion francs compared to the previous week
2026-07-28 -
The Secret History Of The Banking Crisis
2017-08-14 -
SNB Balance Sheet Now Over 100 percent GDP
2016-08-29 -
The relationship between CHF and gold
2016-07-23 -
CHF Price Movements: Correlations between CHF and the German Economy
2016-07-22
Featured and recent
-
VW restructuring has limited impact on Swiss companies -
Yen Stabilizes as Market Awaits US Employment Data -
Is CoreWeave At The Mercy Of The Bond Market? -
AI Bears: Right About The Excess, May Be Wrong On The Trade -
Job adverts for Swiss-based bank posts fall10% -
Chinese retail platform Temu challenges consumers and retailers -
Hans-Hermann Hoppe: “The State is the greatest parasite in history”
-
Switzerland has worst summer potato harvest on record -
Petition launched to stop outsourcing of Swiss Post, Swisscom jobs -
Swiss summer storm damage to cost insurers hundreds of millions of francs
More from this category
VW restructuring has limited impact on Swiss companies4 Sep 2026
Yen Stabilizes as Market Awaits US Employment Data4 Sep 2026
Is CoreWeave At The Mercy Of The Bond Market?4 Sep 2026
AI Bears: Right About The Excess, May Be Wrong On The Trade4 Sep 2026
Job adverts for Swiss-based bank posts fall10%4 Sep 2026
Chinese retail platform Temu challenges consumers and retailers4 Sep 2026
- Hans-Hermann Hoppe: “The State is the greatest parasite in history”
3 Sep 2026
Switzerland has worst summer potato harvest on record3 Sep 2026
Petition launched to stop outsourcing of Swiss Post, Swisscom jobs3 Sep 2026
Swiss summer storm damage to cost insurers hundreds of millions of francs3 Sep 2026
Geneva Airport generates over CHF3 billion for regional economy: report3 Sep 2026
The Yen Squeezes Higher, Though Official Fingerprints are Elusive3 Sep 2026
- Ben Bernanke Didn’t Prevent a Depression. He Prevented a Recovery
3 Sep 2026
Swiss economy posts strong growth in second quarter3 Sep 2026
Global Bond Yields Fret Inflation & Deficits3 Sep 2026
Nestlé to invest over CHF300 million in Brazil3 Sep 2026
Swiss inflation rate jumps to highest level in two years3 Sep 2026
The numbers behind China’s pharma rise3 Sep 2026
- Christoph Ammann to Lead SNB Bank Council as President From May 2027
3 Sep 2026
China’s pharma companies turn to Europe for growth3 Sep 2026











